基本信息:
- 专利标题： 一种禽流感病毒、禽腺病毒二联灭活疫苗
- 专利标题（英）：Combined inactivated vaccine for avian influenza virus and fowl adenovirus
- 申请号：CN201610099573.3 申请日：2016-02-23
- 公开(公告)号：CN105582533A 公开(公告)日：2016-05-18
- 发明人： 李陆梅 , 宫晓 , 刘新文 , 朱艳梅 , 徐保娟
- 申请人： 青岛易邦生物工程有限公司
- 申请人地址： 山东省青岛市红岛经济区红岛街道泉大路东大洋社区岙东南路21号
- 专利权人： 青岛易邦生物工程有限公司
- 当前专利权人： 青岛易邦生物工程有限公司
- 当前专利权人地址： 山东省青岛市红岛经济区红岛街道泉大路东大洋社区岙东南路21号
- 代理机构： 北京科亿知识产权代理事务所
- 代理人： 汤东凤
- 生物保藏信息： CCTCC NO: V201517 20150429; CCTCC NO: V201541 20151015
- 主分类号： A61K39/145
- IPC分类号： A61K39/145 ; A61K39/235 ; A61P31/14 ; A61P31/16 ; C12N7/00 ; C12N7/04 ; C12R1/93
The invention provides a combined inactivated vaccine for an avian influenza virus and a fowl adenovirus. An H9 subtype avian influenza virus QDY strain and an I-group 4-type aviadenovirus YBAV-4 new strain used by the vaccine are high in TCID50/EID50 valence and good in immunogenicity and can well withstand attacks of the H9 avian virus and various local separate viruses. The vaccine prepared by the invention is good in safety, and free of local and whole-body adverse effects caused by the vaccine. Through analysis of characters, a safety test and efficacy test data in a storage-life test, the combined vaccine is free of an obvious difference from a single vaccine of a similar product in effect, and is stable and effective; the efficacy test result proves that the antibodies of the combined vaccine and two single vaccines are kept at a high level and are faster in antibody generation of similar products; and a control group antibody is negative.
公开/授权文献:
- CN105582533B 一种禽流感病毒、禽腺病毒二联灭活疫苗 公开/授权日：2020-06-09
IPC结构图谱:
| A | 人类生活必需 |
| --A61 | 医学或兽医学；卫生学 |
| ----A61K | 医用、牙科用或梳妆用的配制品 |
| ------A61K39/00 | 含有抗原或抗体的医药配制品 |
| --------A61K39/12 | .病毒性抗原 |
| ----------A61K39/145 | ..正黏液病毒科，例如流感病毒属 |